Ricardo Horacio Roda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ricardo Horacio Roda has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Alice B. Schindler
Neurogenetics Branch National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda Maryland
4 shared publicationsCraig Blackstone
Neurogenetics Branch National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda Maryland
4 shared publicationsAhmet Hoke
Solomon H. Snyder Department of Neuroscience and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
2 shared publicationsAndrea M. Corse
Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publications- Ahmet Hoke
Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA
1 shared publication Ajay Bharti
1 shared publication
Latest Publications
- Open Access
- 13 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26861
Successful Treatment of Paraneoplastic Neuropathy and Pruritis With Scrambler Therapy: A Case Report
Paraneoplastic neuropathy, including pruritis, remains a vexing problem as it often does not resolve even with successful treatment of cancer. Scrambler Therapy is a superficial form of neuromodulation that replaces the pain signal with “non-pain information” that is approved for chronic and neuropathic pain, with few side effects. We report here two cases of paraneoplastic neuropathy, one with additional pruritis, that both responded satisfactorily to Scrambler Therapy with no side effects.
- 13 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26861
Open AccessSuccessful Treatment of Paraneoplastic Neuropathy and Pruritis With Scrambler Therapy: A Case Report
Paraneoplastic neuropathy, including pruritis, remains a vexing problem as it often does not resolve even with successful treatment of cancer. Scrambler Therapy is a superficial form of neuromodulation that replaces the pain signal with “non-pain information” that is approved for chronic and neuropathic pain, with few side effects. We report here two cases of paraneoplastic neuropathy, one with additional pruritis, that both responded satisfactorily to Scrambler Therapy with no side effects.
- 10 March 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 98, 99-102
The association between educational attainment and SCA 3 age of onset and disease course
- 10 March 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 98, 99-102
The association between educational attainment and SCA 3 age of onset and disease course
- Open Access
- 8 June 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (11) , 1186-1196
Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases
Background: We used a multimodal approach including detailed phenotyping, whole exome sequencing (WES) and candidate gene filters to diagnose rare neurological diseases in individuals referred by tertiary neurology centres.Methods: WES was performed on 66 individuals with neurogenetic diseases using candidate gene filters and stringent algorithms for assessing sequence variants. Pathogenic or likely pathogenic missense variants were interpreted using in silico prediction tools, family segregation analysis, previous publications of disease association and relevant biological assays.Results: Molecular diagnosis was achieved in 39% (n=26) including 59% of childhood-onset cases and 27% of late-onset cases. Overall, 37% (10/27) of myopathy, 41% (9/22) of neuropathy, 22% (2/9) of MND and 63% (5/8) of complex phenotypes were given genetic diagnosis. Twenty-seven disease-associated variants were identified including ten novel variants inFBXO38, LAMA2, MFN2, MYH7, PNPLA6, SH3TC2andSPTLC1. Single-nucleotide variants (n=10) affected conserved residues within functional domains and previously identified mutation hot-spots. Established pathogenic variants (n=16) presented with atypical features, such as optic neuropathy in adult polyglucosan body disease, facial dysmorphism and skeletal anomalies in cerebrotendinous xanthomatosis, steroid-responsive weakness in congenital myasthenia syndrome 10. Potentially treatable rare diseases were diagnosed, improving the quality of life in some patients.Conclusions: Integrating deep phenotyping, gene filter algorithms and biological assays increased diagnostic yield of exome sequencing, identified novel pathogenic variants and extended phenotypes of difficult to diagnose rare neurogenetic disorders in an outpatient clinic setting.
- 8 June 2021
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 92 (11) , 1186-1196
Open AccessImproving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases
Background: We used a multimodal approach including detailed phenotyping, whole exome sequencing (WES) and candidate gene filters to diagnose rare neurological diseases in individuals referred by tertiary neurology centres.Methods: WES was performed on 66 individuals with neurogenetic diseases using candidate gene filters and stringent algorithms for assessing sequence variants. Pathogenic or likely pathogenic missense variants were interpreted using in silico prediction tools, family segregation analysis, previous publications of disease association and relevant biological assays.Results: Molecular diagnosis was achieved in 39% (n=26) including 59% of childhood-onset cases and 27% of late-onset cases. Overall, 37% (10/27) of myopathy, 41% (9/22) of neuropathy, 22% (2/9) of MND and 63% (5/8) of complex phenotypes were given genetic diagnosis. Twenty-seven disease-associated variants were identified including ten novel variants inFBXO38, LAMA2, MFN2, MYH7, PNPLA6, SH3TC2andSPTLC1. Single-nucleotide variants (n=10) affected conserved residues within functional domains and previously identified mutation hot-spots. Established pathogenic variants (n=16) presented with atypical features, such as optic neuropathy in adult polyglucosan body disease, facial dysmorphism and skeletal anomalies in cerebrotendinous xanthomatosis, steroid-responsive weakness in congenital myasthenia syndrome 10. Potentially treatable rare diseases were diagnosed, improving the quality of life in some patients.Conclusions: Integrating deep phenotyping, gene filter algorithms and biological assays increased diagnostic yield of exome sequencing, identified novel pathogenic variants and extended phenotypes of difficult to diagnose rare neurogenetic disorders in an outpatient clinic setting.
- 4 May 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (2) , e156-e165
Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy
Objective The primary objective of this study was to evaluate the correlation of large mitochondrial DNA (mtDNA) deletions in skin samples of people with HIV (PWH) with measures of neuropathy and prior exposure to therapy. We hypothesized that deletions would be associated with neuropathy. As secondary objectives, we determined the correlation of deletion burden with demographic data and neuropathy measures. Methods In this retrospective cohort study, we measured the accumulation of large mtDNA deletions in skin biopsies from PWH recruited as part of the AIDS Clinical Trials Group (ACTG). Our cohort includes individuals with and without sensory neuropathy, as well as individuals with normal or abnormal skin biopsies. Skin biopsies, sural and peroneal nerve conduction studies, total neuropathy score, and deletion burden scores were measured, along with baseline demographic data such as age, CD4+ cell count, viral counts, and prior nucleoside reverse transcriptase inhibitor exposures. Results Sixty-seven PWH were enrolled in the study. The mean age of the cohort (n = 67) was 44 years (SD 6.8, range 32–65 years), and 9 participants were female. The mean CD4+ T-cell count was 168 cells/mm3 (SD 97 cells/mm3, range 1–416 cells/mm3) and mean viral load was 51,129 copies/mL (SD 114,586 copies/mL, range 147–657,775 copies/mL). We determined that there was a correlation between the total mtDNA deletion and intraepidermal nerve fiber density (IENFD) (r = −0.344, p = 0.04) and sural nerve amplitude (r = −0.359, p = 0.004). Conclusions Both IENFD and sural nerve amplitude statistically correlate with mitochondrial mutation burden in PWH, specifically in those with HIV-associated sensory neuropathy as assessed by skin biopsy.
- 4 May 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (2) , e156-e165
Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy
Objective The primary objective of this study was to evaluate the correlation of large mitochondrial DNA (mtDNA) deletions in skin samples of people with HIV (PWH) with measures of neuropathy and prior exposure to therapy. We hypothesized that deletions would be associated with neuropathy. As secondary objectives, we determined the correlation of deletion burden with demographic data and neuropathy measures. Methods In this retrospective cohort study, we measured the accumulation of large mtDNA deletions in skin biopsies from PWH recruited as part of the AIDS Clinical Trials Group (ACTG). Our cohort includes individuals with and without sensory neuropathy, as well as individuals with normal or abnormal skin biopsies. Skin biopsies, sural and peroneal nerve conduction studies, total neuropathy score, and deletion burden scores were measured, along with baseline demographic data such as age, CD4+ cell count, viral counts, and prior nucleoside reverse transcriptase inhibitor exposures. Results Sixty-seven PWH were enrolled in the study. The mean age of the cohort (n = 67) was 44 years (SD 6.8, range 32–65 years), and 9 participants were female. The mean CD4+ T-cell count was 168 cells/mm3 (SD 97 cells/mm3, range 1–416 cells/mm3) and mean viral load was 51,129 copies/mL (SD 114,586 copies/mL, range 147–657,775 copies/mL). We determined that there was a correlation between the total mtDNA deletion and intraepidermal nerve fiber density (IENFD) (r = −0.344, p = 0.04) and sural nerve amplitude (r = −0.359, p = 0.004). Conclusions Both IENFD and sural nerve amplitude statistically correlate with mitochondrial mutation burden in PWH, specifically in those with HIV-associated sensory neuropathy as assessed by skin biopsy.
- Open Access
- 27 February 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (4) , 825-830
Prevalence of heart disease in patients with mitochondrial abnormalities on skeletal muscle biopsy
Objective Mitochondrial DNA mutations are associated with an increased risk of heart disease. Whether an increased prevalence of cardiovascular disease is present in patients presenting with mitochondrial abnormalities on skeletal muscle biopsy remains unknown. This study was designed to determine the prevalence of cardiac conduction disease and structural heart disease in patients presenting with mitochondrial abnormalities on skeletal muscle biopsy. Methods This is a retrospective cohort study of 103 patients with mitochondrial abnormalities on skeletal muscle biopsy who were referred for evaluation of muscle weakness at a single tertiary care referral center from 2012 to 2018. Of these patients, 59 (57.3%) had an electrocardiogram available and were evaluated for the presence of conduction disease. An echocardiogram was available in 43 patients (42%) who were evaluated for the presence of structural heart disease. The prevalence of cardiac disease was compared to control cohort populations (Framingham and the Atherosclerosis Risk in Communities, ARIC cohorts). Results Mitochondrial abnormalities associated with cardiac conduction disease (defined as QRS duration ≥ 120 msec) were present in 8.9%, versus 2.0% (p < 0.001) in the Framingham population and 2.6% (p = 0.003) in the ARIC cohort. LV systolic dysfunction (LVEF ≤ 50%) was present in 11.6%, versus 3.6% (p < 0.01) in the Framingham and 3% (p < 0.01) in the ARIC populations. Left ventricular hypertrophy was present in 28.6%, versus 13.6% (p < 0.02) in the Framingham and 10.4% (p < 0.001) in the ARIC populations. Interpretation Given the increased prevalence of cardiovascular disease, patients with mitochondrial abnormalities on skeletal muscle biopsy should undergo routine cardiac screening with physical exam, electrocardiography, and cardiac imaging.
- 27 February 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (4) , 825-830
Open AccessPrevalence of heart disease in patients with mitochondrial abnormalities on skeletal muscle biopsy
Objective Mitochondrial DNA mutations are associated with an increased risk of heart disease. Whether an increased prevalence of cardiovascular disease is present in patients presenting with mitochondrial abnormalities on skeletal muscle biopsy remains unknown. This study was designed to determine the prevalence of cardiac conduction disease and structural heart disease in patients presenting with mitochondrial abnormalities on skeletal muscle biopsy. Methods This is a retrospective cohort study of 103 patients with mitochondrial abnormalities on skeletal muscle biopsy who were referred for evaluation of muscle weakness at a single tertiary care referral center from 2012 to 2018. Of these patients, 59 (57.3%) had an electrocardiogram available and were evaluated for the presence of conduction disease. An echocardiogram was available in 43 patients (42%) who were evaluated for the presence of structural heart disease. The prevalence of cardiac disease was compared to control cohort populations (Framingham and the Atherosclerosis Risk in Communities, ARIC cohorts). Results Mitochondrial abnormalities associated with cardiac conduction disease (defined as QRS duration ≥ 120 msec) were present in 8.9%, versus 2.0% (p < 0.001) in the Framingham population and 2.6% (p = 0.003) in the ARIC cohort. LV systolic dysfunction (LVEF ≤ 50%) was present in 11.6%, versus 3.6% (p < 0.01) in the Framingham and 3% (p < 0.01) in the ARIC populations. Left ventricular hypertrophy was present in 28.6%, versus 13.6% (p < 0.02) in the Framingham and 10.4% (p < 0.001) in the ARIC populations. Interpretation Given the increased prevalence of cardiovascular disease, patients with mitochondrial abnormalities on skeletal muscle biopsy should undergo routine cardiac screening with physical exam, electrocardiography, and cardiac imaging.
- 1 July 2019
- Published by Elsevier in Neuromuscular Disorders
- Vol. 29 (7) , 554-561
Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis
- 1 July 2019
- Published by Elsevier in Neuromuscular Disorders
- Vol. 29 (7) , 554-561
Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis
- 1 January 2019
- Published by Elsevier
- Vol. 145, 67-82
Mitochondrial dysfunction in HIV-induced peripheral neuropathy
- 1 January 2019
- Published by Elsevier
- Vol. 145, 67-82
Mitochondrial dysfunction in HIV-induced peripheral neuropathy
- Open Access
- 1 February 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (1) , e220
Novel hemizygous nonsense mutation in DRP2 is associated with inherited neuropathy
Mutations in DRP2 (OMIM #300052) encoding dystrophin-related protein 2, a 957 amino acid protein, were identified in a single patient with X-linked Charcot-Marie-Tooth (CMT) disease and are associated with familial autism. 1,2 DRP2 is predominantly expressed in the brain and spinal cord and functionally interacts with periaxin (PRX, OMIM #605725), a known causative CMT gene (OMIM #614895 and #145900), in the PRX-DRP2-dystroglycan (PDG) complex. 3 The PDG complex supports and maintains Cajal bands, which are cytoplasmic extensions that run along the length of myelinated axons and are required for establishing a proper internodal length. 4-6 A nonsense DRP2 c.805C>T (Q269X) mutation was found in a patient with sensorimotor neuropathy, with intermediate conduction velocities and absence of Cajal bands within dermal nerves. 1 Here, we report another patient with a novel nonsense mutation in DRP2 with sensorimotor polyneuropathy and histologic myelin abnormalities. This report extends the known mutation spectrum of DRP2 and provides further evidence of its association with inherited neuropathy. Case report The index patient is a 42-year-old man who developed fatigue, numbness and tingling in his fingers and toes, and headaches at the age of 18. Over time, he developed patchy burning in his extremities, intermittent numbness in his face, heat intolerance, and excessive sweating. There was no family history of neuropathy. Nerve conduction studies at the age of 33 demonstrated mildly slowed conduction velocities and prolonged F-wave latencies in the lower extremities. A left sural nerve biopsy showed fibers with tomaculae, thinly myelinated fibers, and a small focus of perivascular epineurial inflammation. A lumbar puncture was performed and showed normal CSF protein levels and cell counts. Testing for diabetes mellitus, Sjogren syndrome, HIV, and Lyme disease was negative, and hexosaminidase A and α-galactosidase levels were normal. Testing for mutations of PMP22, MFN2, and GBJ1 was negative.
- 1 February 2018
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 4 (1) , e220
Open AccessNovel hemizygous nonsense mutation in DRP2 is associated with inherited neuropathy
Mutations in DRP2 (OMIM #300052) encoding dystrophin-related protein 2, a 957 amino acid protein, were identified in a single patient with X-linked Charcot-Marie-Tooth (CMT) disease and are associated with familial autism. 1,2 DRP2 is predominantly expressed in the brain and spinal cord and functionally interacts with periaxin (PRX, OMIM #605725), a known causative CMT gene (OMIM #614895 and #145900), in the PRX-DRP2-dystroglycan (PDG) complex. 3 The PDG complex supports and maintains Cajal bands, which are cytoplasmic extensions that run along the length of myelinated axons and are required for establishing a proper internodal length. 4-6 A nonsense DRP2 c.805C>T (Q269X) mutation was found in a patient with sensorimotor neuropathy, with intermediate conduction velocities and absence of Cajal bands within dermal nerves. 1 Here, we report another patient with a novel nonsense mutation in DRP2 with sensorimotor polyneuropathy and histologic myelin abnormalities. This report extends the known mutation spectrum of DRP2 and provides further evidence of its association with inherited neuropathy. Case report The index patient is a 42-year-old man who developed fatigue, numbness and tingling in his fingers and toes, and headaches at the age of 18. Over time, he developed patchy burning in his extremities, intermittent numbness in his face, heat intolerance, and excessive sweating. There was no family history of neuropathy. Nerve conduction studies at the age of 33 demonstrated mildly slowed conduction velocities and prolonged F-wave latencies in the lower extremities. A left sural nerve biopsy showed fibers with tomaculae, thinly myelinated fibers, and a small focus of perivascular epineurial inflammation. A lumbar puncture was performed and showed normal CSF protein levels and cell counts. Testing for diabetes mellitus, Sjogren syndrome, HIV, and Lyme disease was negative, and hexosaminidase A and α-galactosidase levels were normal. Testing for mutations of PMP22, MFN2, and GBJ1 was negative.
- Open Access
- 14 October 2017
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 4 (11) , 821-824
Multigeneration family with dominant SPG30 hereditary spastic paraplegia
Autosomal recessive KIF1A missense mutations cause hereditary spastic paraplegia (HSP) type SPG30, while recessive truncations lead to sensory and autonomic neuropathy (HSN2C) and many de novo missense mutations are associated with cognitive impairment. Here, we describe family members across three generations with pure HSP. A heterozygous p.Ser69Leu KIF1A mutation segregates with those afflicted. The same variant was previously reported in a Finnish father and son with pure HSP as well as four members of a Sicilian kindred with more intrafamilial phenotypic variability. This further validates the pathogenicity of the p.Ser69Leu mutation and suggests that it may represent a mutation hot spot.
- 14 October 2017
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 4 (11) , 821-824
Open AccessMultigeneration family with dominant SPG30 hereditary spastic paraplegia
Autosomal recessive KIF1A missense mutations cause hereditary spastic paraplegia (HSP) type SPG30, while recessive truncations lead to sensory and autonomic neuropathy (HSN2C) and many de novo missense mutations are associated with cognitive impairment. Here, we describe family members across three generations with pure HSP. A heterozygous p.Ser69Leu KIF1A mutation segregates with those afflicted. The same variant was previously reported in a Finnish father and son with pure HSP as well as four members of a Sicilian kindred with more intrafamilial phenotypic variability. This further validates the pathogenicity of the p.Ser69Leu mutation and suggests that it may represent a mutation hot spot.
- Open Access
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 3 (3) , e150
SCA8 should not be tested in isolation for ataxia
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 3 (3) , e150
Open AccessSCA8 should not be tested in isolation for ataxia